Diakonos Oncology

Executive Summary

Diakonos Oncology is a clinical-stage biotechnology company pioneering dendritic cell vaccines for hard-to-treat cancers. Its lead candidate, DOC1021, has received FDA Fast Track designation and employs a proprietary 'double-loading' technique that primes the immune system to recognize tumors as virally infected cells, thereby triggering a potent anti-viral immune response. In 2025, the company initiated a Phase 2 trial for DOC1021 in glioblastoma, building on promising Phase 1 data showing durable responses and manageable safety. Diakonos is well-positioned to address significant unmet needs in oncology, leveraging a novel mechanism distinct from checkpoint inhibitors and CAR-T therapies. With a strong scientific foundation and a clear clinical path, the company represents an attractive opportunity in the immuno-oncology space.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim efficacy data for DOC1021 in glioblastoma60% success
• Q1 2027FDA end-of-Phase 2 meeting to align on pivotal trial design75% success
• Q3 2026Potential partnership or licensing deal for DOC1021 outside U.S.40% success